Lei, Chaofang, Chen, Jiaxu, Huang, Zhen et al. · Frontiers in pharmacology · 2023 · DOI
This study tested whether ginsenoside Rg1, a compound from ginseng, could reduce fatigue in rats with chronic fatigue syndrome. Researchers found that the treatment reversed fatigue behavior and corrected abnormal metabolism patterns in the rats' blood, particularly affecting molecules called taurine and mannose 6-phosphate. The results suggest ginseng-derived compounds might help ME/CFS patients, though human studies would be needed to confirm this.
ME/CFS patients urgently need new treatment options, and this study provides preclinical evidence that a traditional plant compound may target specific metabolic dysfunctions underlying fatigue. Identifying specific biomarkers and molecular pathways affected by ginsenoside Rg1 could guide future drug development and personalized treatment approaches for ME/CFS.
This rat study does not prove that ginsenoside Rg1 will work in human ME/CFS patients—animal models often fail to translate to clinical efficacy. The study demonstrates correlation between drug administration and changes in metabolic markers and EGFR expression, but does not establish that EGFR regulation is the sole or primary mechanism of fatigue reversal. Additionally, it does not compare ginsenoside Rg1 to existing treatments or establish optimal dosing and safety profiles for humans.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →